We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Regulus Therapeutics Inc (RGLS) NPV

Sell:$0.34 Buy:$0.35 Change: $0.0049 (1.44%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Sell:$0.34
Buy:$0.35
Change: $0.0049 (1.44%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Sell:$0.34
Buy:$0.35
Change: $0.0049 (1.44%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.

Contact details

Address:
4224 CAMPUS POINT COURT, SUITE 210
SAN DIEGO
92121
United States
Telephone:
+1 (858) 2026300
Website:
www.regulusrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RGLS
ISIN:
US75915K2006
Market cap:
$29.60 million
Shares in issue:
87.05 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joseph Hagan
    President, Chief Executive Officer, Director
  • Crispina Calsada
    Chief Financial Officer
  • Christopher Aker
    Senior Vice President, General Counsel
  • Denis Drygin
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.